General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FWYLZ
ADC Name
Zanidatamab zovodotin
Synonyms
ZW 49; ZW-49; ZW49; anti-HER2 x HER2 ADC
   Click to Show/Hide
Organization
Zymeworks BC, Inc.; BeiGene Ltd.
Drug Status
Phase 1
Indication
In total 4 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 1
Esophageal cancer [ICD11:2B70]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
HER2(+) solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Drug-to-Antibody Ratio
2
Antibody Name
Zanidatamab
 Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (HER2 ECD2); Receptor tyrosine-protein kinase erbB-2 (HER2 ECD4)
 Antigen Info 
Payload Name
ZD02044
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Mc-PEG3-Val-Cit
 Linker Info 
Combination Type
Zovodotin (ZD001-02044)
Puchem SID
472419995 , 433770841
Drugbank ID
DB15472

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.